Navigating the New Era of mHSPC and nmCRPC Data-Driven Strategies for Therapy Selection CME/CNE/CPE Sunday, 25 October 2026, 13:00 - 14:30 CET MURCIA AUDITORIUM, HALL 3, IFEMA MADRID, MADRID, SPAIN

https://events.medscapelive.org/website/98811/?utm_campaign=462515.01a_esmo_email&utm_source=edu&utm_medium=em&utm_content=ext Join us for an interactive symposium that will transform your approach to prostate cancer treatment. This dynamic 90-minute program brings together leading experts to decode the latest evidence in metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). Through engaging deep dives and expert roundtable discussions, you'll explore groundbreaking data from pivotal clinical trials and real-world evidence that are reshaping treatment paradigms. Discover how to optimize therapy selection using androgen receptor pathway inhibitors, navigate the complexities of doublet vs triplet therapy, and master risk stratification strategies that put patients first. You'll gain practical insights on balancing efficacy with quality of life, managing treatment-related adverse events, and implementing multidisciplinary care approaches. Walk away with confidence to initiate early intensification strategies that extend survival, delay disease progression, and improve patient outcomes in your clinical practice. IMPORTANT NOTICE To attend this symposium, whether in person or virtually, you must first register directly with ESMO Congress 2026. Please visit the official congress website for full registration details and requirements.